Danavish Glimepiride+Metformin+Voglibose 1mg/500mg/0.2mg Tablet SR
Marketer
Danavish Healthcare
Salt Composition
Glimepiride (1mg) + Metformin (500mg) + Voglibose (0.2mg)
Overview Danavish Glimepiride+Metformin+Voglibose 1mg/500mg/0.2mg Tablet SR
This medication, a combination of glimepiride, metformin, and voglibose (Danavish 1mg/500mg/0.2mg SR), is an antidiabetic agent for adult-onset type 2 diabetes. It helps manage blood glucose. Administer this triple-combination tablet with food, consistently at the same time daily for optimal effect. Dosage is determined and adjusted by your physician based on your blood sugar readings. Continuous use is crucial; discontinuation without medical guidance can elevate blood sugar, increasing risks of kidney complications, vision loss, neuropathy, and limb damage. This medicine is only one component of a comprehensive diabetes management plan; a healthy diet, exercise, and weight control (as directed by your doctor) are equally vital. Commonly, low blood sugar (hypoglycemia) occurs. Learn to recognize symptoms like sweating, dizziness, headache, and tremors, and know how to counter them with a fast-acting glucose source (e.g., sugary foods or juice). Alcohol intensifies hypoglycemia risk and should be avoided. Other potential side effects include altered taste, nausea, diarrhea, abdominal discomfort, headaches, swelling (edema), blurred vision, fractures, upper respiratory infections, and weight gain. This medication is contraindicated for type 1 diabetes, diabetic ketoacidosis, or severe kidney/liver impairment. Inform your doctor of any history of heart conditions before starting treatment. Pregnant or lactating individuals should consult their doctor. Regular blood glucose monitoring is essential, along with potential blood tests to track blood cell counts and liver function.
Primary Ingredients of Danavish Glimepiride+Metformin+Voglibose 1mg/500mg/0.2mg Tablet SR
No text provided to rephrase.
Uses of Danavish Glimepiride+Metformin+Voglibose 1mg/500mg/0.2mg Tablet SR
Managing Type 2 Diabetes
Major Benefits of Danavish Glimepiride+Metformin+Voglibose 1mg/500mg/0.2mg Tablet SR:
Consume this medication precisely as prescribed by your physician, adhering to both the dosage and treatment length. Ingest the tablet whole; avoid chewing, crushing, or fracturing it. Danavish Glimepiride+Metformin+Voglibose 1mg/500mg/0.2mg SR tablets should be taken on an empty stomach.
Common Side effects of Danavish Glimepiride+Metformin+Voglibose 1mg/500mg/0.2mg Tablet SR:
- Nausea
- Diarrhea
- Abdominal pain
- Hypoglycemia (low blood glucose level)
- Loss of appetite
How to use Danavish Glimepiride+Metformin+Voglibose 1mg/500mg/0.2mg Tablet SR:
Follow your physician's instructions precisely regarding dosage and treatment length for this medication. Ingest the Danavish Glimepiride+Metformin+Voglibose 1mg/500mg/0.2mg Tablet SR whole; avoid chewing, crushing, or breaking. Administer on an empty stomach.
How Danavish Glimepiride+Metformin+Voglibose 1mg/500mg/0.2mg Tablet SR works:
Danavish SR tablets, containing glimepiride 1mg, metformin 500mg, and voglibose 0.2mg, offer a triple-action approach to diabetes management.
SAFETY ADVICE
AlcoholUNSAFE
Concurrent alcohol use and Danavish Glimepiride+Metformin+Voglibose 1mg/500mg/0.2mg SR tablets is inadvisable.
PregnancyCONSULT YOUR DOCTOR
The combination drug Danavish Glimepiride+Metformin+Voglibose 1mg/500mg/0.2mg SR tablet might pose risks during pregnancy. While human research is scarce, animal studies indicate potential harm to a developing fetus. A physician will assess the advantages against possible dangers prior to prescribing. Seek medical advice.
Breast feedingCONSULT YOUR DOCTOR
Use of Danavish Glimepiride+Metformin+Voglibose 1mg/500mg/0.2mg SR tablets during breastfeeding is likely unsafe. Studies in humans indicate potential transfer to breast milk, posing a risk to the infant.
DrivingCAUTION
Driving ability can be impaired by both hypoglycemia and hyperglycemia. Refrain from driving if you experience these blood sugar imbalances.
KidneyUNSAFE
The combination medication Danavish Glimepiride+Metformin+Voglibose 1mg/500mg/0.2mg SR tablet is likely unsuitable for individuals with impaired kidney function and its use should be avoided. Medical advice is necessary. Furthermore, this medication is contraindicated in patients experiencing severe kidney disease.
LiverCAUTION
Patients with liver impairment should use Danavish Glimepiride+Metformin+Voglibose 1mg/500mg/0.2mg Tablet SR cautiously, potentially requiring dosage modification. Medical advice is essential. Low initial doses are typically prescribed for those with mild to moderate liver disease; however, its use is contraindicated in patients with severe hepatic dysfunction.
What if you forget to take Danavish Glimepiride+Metformin+Voglibose 1mg/500mg/0.2mg Tablet SR :
Should you forget a dose of Danavish Glimepiride+Metformin+Voglibose 1mg/500mg/0.2mg SR Tablet, administer it promptly. Nevertheless, if your next scheduled dose is imminent, omit the missed dose and resume your usual dosing regimen. Avoid taking a double dose.
Facts to Know About Danavish Glimepiride+Metformin+Voglibose 1mg/500mg/0.2mg Tablet SR
| Label | Value |
|---|---|
| Developing Habits | No. |
| Treatment Category | Diabetes Management |
3,018 People bought this recently